Novye podkhody k terapii bolezni Itsenko-Kushinga
- Authors: Antsiferov M.B1
-
Affiliations:
- Issue: No 16 (2014)
- Pages: 30-36
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287409
- ID: 287409
Cite item
Open Access
Access granted
Abstract
Treatment of Cushing’s disease (CD) is a clinical challenge, an effective solution of which depends on the accuracy of the diagnosis, a correct assessment of the severity of hypercortisolism and the severity of the disease, as well as an individual approach to the choice of treatments. Introduction of pasireotide (Signifor) into clinical practice allows to achieve clinical and laboratory remission of CD and reduce the size of the tumor. Thus, pasireotide is an effective drug for the specific treatment of corticotroph adenomas in patients with CD.
Keywords
Full Text
References
- Etxabe and Vazquez. Morbidity and mortality in Cushing's disease: an epidemiological report. Clin. Endocrinol. 2004; 40: 479-84.
- Дедов И.И., Мельниченко Г.А. Болезнь Иценко-Кушинга. Методические рекомендации, МЗ РФ, 2012.
- Белая Ж.Е. Ранняя диагностика эндогенного гиперкортицизма. Канонический сигнальный путь и изменение костного метаболизма при глюкокортикоидном остеопорозе. Дисс.. докт. мед. наук. М., 2014.
- Finding J., Raff Н. Screening and Diagnosis Cushing syndrome. Endocrinol. Metab. Clin. Noth. Am. 2005; 385-402.
- Castinetti F., Morange I., Conte-Devolx B., Brue T. Cushing disease. Orphanet Journal of Rare diseases, 2012; 7: 41.
- Gardner D., Shoback D. Greenspan s. Basic and Clinical Endocrinology, 2010; 156-65.
- Melmed S., Polonsky K., Reed Larsen P., et al. Textbook of Endocrinology, 12th edition, Philadelphia: Elsevier/Saunders, 2011.
- Praw S.S.1, Heaney A.P. Medical treatment of Cushing's disease: Overview and recent findings. Int. J. Gen. Med. 2009; 2: 209-17.
- Nieman L.K., et. al. The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline JCEM, 2008, 93: 1526-40.
- Guaraldi F.1, Salvatori R. Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med. 2012 Mar-Apr; 25(2): 199-208.
- Ferone D., Pivonello C., Vitale G., et al. Molecular basis of pharmacological therapy in Cushing's disease. Endocrine, 2014, Jun; 46(2): 181-98.
- Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., Дедов И.И. Современный взгляд на скрининг и диагностику эндогенного гиперкортицизма. Проблемы эндокринологии. 2012; 58: 35-41.
- Atkinson A.B., Kennedy A., Wiggam M.I., McCance D.R., Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin. Endocrinol. 2005; 63(5): 549-59.
- Brada M., Rajan B., Traish D., et al. The longterm efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin. Endocrinol. 1993; 38: 571-78.
- Valderrabano P., Aller J.,Garcia-Valdecasas L., et al. Results of repeated transsphenoidal surgery in Cushing's disease. Long-term follow-up. Endocrinol. Nutr. 2014; 61(4): 176-83.
- Bertagna X., Bertagna C., Laudat M.H., Husson J.M., Girard F., Luton J.P. Pituitary-adrenal response to the antiglucocorticoid action of RU-486 in Cushing's syndrome. J. Clin. Endocrinol. Metab. 1986; 63(3): 639.
- Castinetti F., Morange I., Jaquet P., et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.Eur. J. Endocrinol. 2008; 158(1): 91-9.
- Korlym (mifepristone) tablets prescribing information. Corcept Therapeutics Inc. 2012.
- Theodoropoulou M., Stalla G.K. Somatostatin receptors: from signaling to clinical practice. Arch. Pharmacol., 1994; 350: 441, Front Neuroendocrinol. 2013; 34(3): 228-52.
- Van der Hoek J., Lamberts S.W., Hofland L.J. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur. J. Endocrinol. 2007; 156 (Suppl. 1): S45-51.
- Trementino L., Cardinaletti M., Concettoni C., et al. Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. Pituitary. 2014; 31.
- Colao A., Petersenn S., Newell-Price J., et al. Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. N. Engl. J. Med. 2012; 366(10): 914-24.
- Trementino L., Cardinaletti M., Concettoni C., et al. Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.Pituitary. 2014.
- Breitschaft A., Hu K., Hermosillo Resendiz K., et al. Management of hyperglycemia associated with pasireotide (S0M230): healthy volunteer study. Diabetes Res. Clin. Pract. 2014; 103(3): 458-65.
- Reznik Y., Bertherat J., Borson-Chazot F., et al. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Diabetes Metab. 2012.
Supplementary files
